| Title: | Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription |
| Authors: | Thomas, D Powell, JA Vergez, F Segal, DH Nguyen, NYN Baker, A Teh, TC Barry, EF Sarry, JE Lee, EM Nero, TL Jabbour, AM Pomilio, G Green, BD Manenti, S Glaser, SP Parker, MW Lopez, AF Ekert, PG Lock, RB Huang, DCS Nilsson, SK Recher, C Wei, AH Guthridge, MA |
| Issue Year: | 2013 |
| Publisher | AMER SOC HEMATOLOGY |
| Series | BLOOD: 122(5): 738-748 |
| Abstract | Resistance to cell death is a hallmark of cancer and renders transformed cells resistant to multiple apoptotic triggers. The Bcl-2 family member, Mcl-1, is a key driver of cell survival in diverse cancers, including acute myeloid leukemia (AML). A screen for compounds that downregulate Mcl-1 identified the kinase inhibitor, PIK-75, which demonstrates marked proapoptotic activity against a panel of cytogenetically diverse primary human AML patient samples. We show that PIK-75 transiently blocks Cdk7/9, leading to transcriptional suppression of MCL-1, rapid loss of Mcl-1 protein, and alleviation of its inhibition of proapoptotic Bak. PIK-75 also targets the p110 alpha isoform of PI3K, which leads to a loss of association between Bcl-x(L) and Bak. The simultaneous loss of Mcl-1 and Bcl-x(L) association with Bak leads to rapid apoptosis of AML cells. Concordantly, low Bak expression in AML confers resistance to PIK-75-mediated killing. On the other hand, the induction of apoptosis by PIK-75 did not require the expression of the BH3 proteins Bim, Bid, Bad, Noxa, or Puma. PIK-75 significantly reduced leukemia burden and increased the survival of mice engrafted with human AML without inducing overt toxicity. Future efforts to cotarget PI3K and Cdk9 with drugs such as PIK-75 in AML are warranted. |
| URI: | https://publications.svi.edu.au/publications/1667 |
| Other Identifiers | 10.1182/blood-2012-08-447441 |
| Publication type | Article |
| Grant ID | GNT1021645 |
| Find it online | http://www.bloodjournal.org/content/bloodjournal/122/5/738.full.pdf |